News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Addex Therapeutics (ADXN.SW) Licensee Completes Enrollment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression



10/29/2013 9:30:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that Janssen Research & Development, LLC, on behalf of Janssen Pharmaceuticals, Inc., has completed enrollment of 120 patients in a multicenter, double-blind, Phase 2 study of ADX71149 in adults with major depressive disorder who are also suffering anxiety symptoms.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES